Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.48 |
| ▸ | CDC25B | P30305 | 8/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.45 |
| ▸ | GJB2 | P29033 | 2/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19731873 | 1.00 | NT5E (0.49) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL22677462 | 0.91 | NT5E (0.50) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL22677737 | 0.91 | NT5E (0.50) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL12871701 | 0.88 | NT5E (0.47) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL14365863 | 0.88 | NT5E (0.47) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL14365870 | 0.88 | NT5E (0.47) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL8055015 | 0.88 | NT5E (0.51) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL8055010 | 0.88 | NT5E (0.51) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL9009910 | 0.88 | NT5E (0.51) | NT5EPTPN1PTPN2PTPN11CDC25B | |
| SCHEMBL8227941 | 0.87 | NT5E (0.59) | NT5EPTPN1PTPN2PTPN11CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336784-B2 | Methods for modular synthesis of N-glycans and arrays thereof | ACADEMIA SINICA (TW) | 2019-07-02 | — | — | US | disclosed |
| US-20170362265-A1 | METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF | ACADEMIA SINICA (TW) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362265-A1 | METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF | SIGLEC7, SIGLEC9, CD4 | NT5E 314/4885PTPN1 185/4885PTPN2 210/4885 |
| US-10336784-B2 | Methods for modular synthesis of N-glycans and arrays thereof | SIGLEC7, SIGLEC9, CD4 | NT5E 314/4885PTPN1 185/4885PTPN2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.